The cost of mood disorders

Psychiatry

Volumn 8, Issue 2, 2009, Pages 76-80

  Patel, Anita ^a  

^a NONE

Author keywords

bipolar disorder; cost effectiveness; costs; depression; economic evaluation; mood disorders; psychological therapies; resources; SSRI; tricyclic

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; FLUOXETINE; LITHIUM; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

BIPOLAR DISORDER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MENTAL HEALTH CARE; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW;

EID: 58349090458     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2008.10.021     Document Type: Review

References (25)

1. In: Murray C., and Lopez A.D. (Eds). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (1996), Harvard University Press, Cambridge, MA
2. Lepine J.P., Gastpar M., Mendlewicz J., and Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12 (1997) 19-29
3. Greener M.J., and Guest J.F. Do antidepressants reduce the burden imposed by depression on employers?. CNS Drugs 19 (2005) 253-264
4. Greenberg P.E., Stiglin L.E., Finkelstein S.N., and Berndt E.R. The economic burden of depression in 1990. J Clin Psychiatry 54 (1993) 405-418
5. Rupp A. The economic consequences of not treating depression. Br J Psychiatry 166 suppl 27 (1995) 2933
6. Kind P., and Sorensen J. The costs of depression. Int Clin Psychopharmacol 7 (1993) 191-195
7. Jonsson B., and Bebbington P.E. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 164 (1994) 665-673
8. Thomas C.M., and Morris S. Costs of depression among adults in England in 2000. Br J Psychiatry 183 (2003) 514-519
9. Das Gupta R., and Guest J.F. Annual cost of bipolar disorder to UK society. Br J Psychiatry 180 (2002) 227-233
10. Wyatt R.J., and Henter I. An economic evaluation of manic-depressive illness, 1991. Soc Psychiatry Psychiatr Epidemiol 30 (1995) 213-219
11. In: Knapp M. (Ed). The economic evaluation of mental health care (1995), Arena, Aldershot
12. Fenwick E., and Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 187 (2005) 106-108
13. Chisholm D.H., Healey A.T., and Knapp M.R.J. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol 32 (1997) 68-75
14. Pirraglia P.A., Rosen A.B., Hermann R.C., Olchanski N.V., and Neumann P. Cost-utility analysis studies of depression management: a systematic review. Am J Psychiatry 161 (2004) 2155-2162
15. Hotopf M., Lewis G., and Norman C. Are SSRIs a cost-effective alternative to tricyclics?. Br J Psychiatry 168 (1996) 404-409
16. Frank L., Revicki D.A., Sorensen S.V., and Shih Y.C. The economics of selective serotonin reuptake inhibitors in depression. A critical review. CNS Drugs 15 (2001) 59-83
17. Woods S.W., and Baker B.C. Cost-effectiveness of newer antidepressants. Curr Opin Psychiatry 10 (1997) 95-101
18. Barrett B., Byford S., and Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 84 (2005) 1-13
19. Keck P.E., McElroy S.L., and Bennett J.A. Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry 57 suppl 13 (1996) 13-18
20. Montgomery S., Doyle J.J., Stern L., and McBurney C.R. Economic considerations in the prescribing of third-generation antidepressants. Pharmacoeconomics 23 (2005) 477-491
21. Iqbal S.U., and Prashker M. Pharmacoeconomic evaluation of antidepressants. A critical appraisal of methods. Pharmacoeconomics 23 (2005) 595-606
22. Bower P., Byford S., Barber J., et al. Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses. BMJ 326 (2003) 1247-1250
23. National Institute for Health and Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guidance 23 (2004), NICE, London
24. National Institute for Health and Clinical Excellence. Depression in children and young people. National clinical practice Guideline 28. Londan: NICE, 2005.
25. Lam D.H., McCrone P., Wright K., and Kerr N. Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. Br J Psychiatry 186 (2005) 500-506